KHONDRION
Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, the company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.
KHONDRION
Industry:
Biotechnology Pharmaceutical
Founded:
2012-01-01
Address:
Nijmegen, Gelderland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.khondrion.com
Total Employee:
11+
Status:
Active
Contact:
+31 24 361 75 05
Total Funding:
3.34 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Khondrion
Key Employee Changes
| Date | New article |
|---|---|
| 2020-02-07 | Khondrion appoints Rob van Maanen as Chief Medical Officer Khondrion |
Official Site Inspections
http://www.khondrion.com Semrush global rank: 9.51 M Semrush visits lastest month: 145
- Host name: s927.whserver.nl
- IP address: 87.239.9.27
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "Khondrion"
About us - Khondrion
About Khondrion. Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease. Based on proprietary science …See details»
Khondrion - Crunchbase Company Profile & Funding
Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in …See details»
Khondrion - MitoWorld
Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of …See details»
About us oud - Khondrion
Khondrion is supported by a group of strategic supporters including the Dutch Foundations Energy4All, Join4Energy, Road4Energy, Ride4Kids, Tim Foundation, and Zeldzame Ziekten Fonds, Khondrion has also received …See details»
Khondrion BV - Drug pipelines, Patents, Clinical trials - Synapse
Explore Khondrion BV with its drug pipeline, therapeutic area, technology platform, 9 clinical trials, 8 news, Disease Domain:Nervous System Diseases, Endocrinology and Metabolic Disease, …See details»
Khondrion Company Profile 2024: Valuation, Funding & Investors
Khondrion General Information Description. Operator of a pharmaceutical company intended to develop small molecule therapeutics for mitochondrial-related diseases. The company …See details»
Khondrion - VentureRadar
Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. The company is advancing its proprietary science through a …See details»
Khondrion - Products, Competitors, Financials, Employees, …
Khondrion is initially focusing the development of sonlicromanol on PMD patients with the m.3243A>G variant, which is the most common genetic defect causing multi-systemic PMD …See details»
Khondrion Company Profile - Office Locations, Competitors ... - Craft
Khondrion is a pharmaceutical company discovering and developing therapies targeting the mitochondrial disease. It is engaged in the development of therapies and biomarkers, …See details»
Khondrion - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 1, 2018: Grant - Khondrion …See details»
Jan Smeitink - Founding & CEO @ Khondrion - Crunchbase
Primary Organization . Khondrion . Location Nijmegen, Gelderland, The Netherlands; Regions European Union (EU), Europe, Middle East, and Africa (EMEA) ... Jan is the Founder and …See details»
UMDF and Khondrion Announce The Mito Fund’s ... - Markets Insider
Nov 21, 2024 Like all investments made by The Mito Fund, the Khondrion consideration went through a rigorous review process by UMDF’s Venture Philanthropy Investment Committee, an …See details»
Press Release Distribution and Management - GlobeNewswire
21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical …See details»
Khondrion - PharmaBoardroom
Nov 17, 2015 Khondrion is an innovative Dutch biopharmaceutical company focusing on developing small molecule therapeutics for mitochondrial (-related) diseases. ... (AMD) is an …See details»
UMDF and Khondrion Announce The Mito Fund’s Investment in
21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical …See details»
Khondrion | Lifesciences @ Work
Khondrion is a clinical stage pharmaceutical company focusing on the development of treatments for mitochondrial (-related) diseases and conditions. Since its operational start in 2012 …See details»
Our Science - Khondrion
KHENERGYC – In April 2021 Khondrion commenced its paediatric Phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children.The double blind, placebo …See details»
UMDF and Khondrion Announce The Mito Fund’s Investment in
Nov 21, 2024 Khondrion is currently preparing to initiate a Phase III study investigating the potential of its lead proprietary drug candidate, sonlicromanol, to treat adult patients with PMD …See details»
How Kyndryl’s CHRO led a corporate cultural transformation post …
5 days ago After technology services company Kyndryl separated from IBM, Maryjo Charbonnier was tasked with structuring a whole new organization for 80,000 workers. HR leader Maryjo …See details»
Our Focus - Khondrion
Cognition is an important function of the brain so we can gain knowledge and understanding. These mental processes include thinking, knowing, remembering, judging, planning, …See details»